EN 
FR Let’s reach
for the stars, together.
Developing long-lasting therapeutics against cancer and beyond.
Developing long-lasting therapeutics against cancer and beyond.
Let’s reach
for the stars, together.
Developing long-lasting therapeutics against cancer and beyond.
Let’s reach
for the stars, together.
Developing long-lasting therapeutics against cancer and beyond.
Harnessing the power of stem cells and advances in gene therapy to cure cancer
Stem cells have the amazing capacity of self-renewal and to regenerate new tissues. Decades of research have made gene therapy a reachable reality and is not science fiction anymore. We now have safe and efficient technological tools to modify cells to treat serious diseases.
At Immugenia, we combine the unique properties of stem cells and the power of gene therapy to develop cancer treatments with life-long potential.
Harnessing the power of stem cells and advances in gene therapy to cure cancer
Stem cells have the amazing capacity of self-renewal and to regenerate new tissues. Decades of research have made gene therapy a reachable reality and is not science fiction anymore. We now have safe and efficient technological tools to modify cells to treat serious diseases.
At Immugenia, we combine the unique properties of stem cells and the power of gene therapy to develop cancer treatments with life-long potential.
About us
Immugenia is an early stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. Our proprietary technology allows for the CAR to be expressed selectively in T and NK cells in order to leverage their synergistic activity against cancer.
To enhance accessibility to CAR therapy, Immugenia is advancing research to administer CAR therapy directly in vivo, thus bypassing the need for ex vivo cell modifications. This approach combines our proprietary promoter technology, which allows CAR expression to be selective to T and NK cells, with lentiviral particles specifically designed to target immune cells.
In this process, hematopoietic stem cells (HSCs), T cells, or NK cells are engineered with a CAR whose expression is regulated by our proprietary promoter(s). This targeted expression is confined to the T and NK cell lineages, allowing for continuous replenishment of CAR-T and CAR-NK cells when HSCs are engineered. Additionally, this method incorporates a safety feature that ensures CAR expression is restricted to the intended immune cells, minimizing off-target effects.
Highlights
1 CureSearch for Children’s Cancer 2022, accessed 12 April 2022, <https://curesearch.org/>
